155 related articles for article (PubMed ID: 30698174)
1. Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells.
Xie YQ; Arik H; Wei L; Zheng Y; Suh H; Irvine DJ; Tang L
Biomater Sci; 2019 Mar; 7(4):1345-1357. PubMed ID: 30698174
[TBL] [Abstract][Full Text] [Related]
2. In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes.
Zheng Y; Stephan MT; Gai SA; Abraham W; Shearer A; Irvine DJ
J Control Release; 2013 Dec; 172(2):426-35. PubMed ID: 23770010
[TBL] [Abstract][Full Text] [Related]
3. Multicompartment intracellular self-expanding nanogel for targeted delivery of drug cocktail.
Bahadur K C R; Xu P
Adv Mater; 2012 Dec; 24(48):6479-83. PubMed ID: 23001909
[TBL] [Abstract][Full Text] [Related]
4. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.
Kalbasi A; Shrimali RK; Chinnasamy D; Rosenberg SA
J Immunother; 2010 Sep; 33(7):672-83. PubMed ID: 20664359
[TBL] [Abstract][Full Text] [Related]
5. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
6. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
[TBL] [Abstract][Full Text] [Related]
7. pH Responsive 5-Fluorouracil Loaded Biocompatible Nanogels For Topical Chemotherapy of Aggressive Melanoma.
Sahu P; Kashaw SK; Sau S; Kushwah V; Jain S; Agrawal RK; Iyer AK
Colloids Surf B Biointerfaces; 2019 Feb; 174():232-245. PubMed ID: 30465998
[TBL] [Abstract][Full Text] [Related]
8. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist.
Parisi G; Saco JD; Salazar FB; Tsoi J; Krystofinski P; Puig-Saus C; Zhang R; Zhou J; Cheung-Lau GC; Garcia AJ; Grasso CS; Tavaré R; Hu-Lieskovan S; Mackay S; Zalevsky J; Bernatchez C; Diab A; Wu AM; Comin-Anduix B; Charych D; Ribas A
Nat Commun; 2020 Jan; 11(1):660. PubMed ID: 32005809
[TBL] [Abstract][Full Text] [Related]
9. In situ forming reduction-sensitive degradable nanogels for facile loading and triggered intracellular release of proteins.
Chen W; Zheng M; Meng F; Cheng R; Deng C; Feijen J; Zhong Z
Biomacromolecules; 2013 Apr; 14(4):1214-22. PubMed ID: 23477570
[TBL] [Abstract][Full Text] [Related]
10. One-pot synthesis of doxorubicin-loaded multiresponsive nanogels based on hyperbranched polyglycerol.
Sousa-Herves A; Wedepohl S; Calderón M
Chem Commun (Camb); 2015 Mar; 51(25):5264-7. PubMed ID: 25757793
[TBL] [Abstract][Full Text] [Related]
11. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery.
Tang L; Zheng Y; Melo MB; Mabardi L; Castaño AP; Xie YQ; Li N; Kudchodkar SB; Wong HC; Jeng EK; Maus MV; Irvine DJ
Nat Biotechnol; 2018 Sep; 36(8):707-716. PubMed ID: 29985479
[TBL] [Abstract][Full Text] [Related]
12. Targeted nanogel conjugate for improved stability and cellular permeability of curcumin: synthesis, pharmacokinetics, and tumor growth inhibition.
Wei X; Senanayake TH; Bohling A; Vinogradov SV
Mol Pharm; 2014 Sep; 11(9):3112-22. PubMed ID: 25072100
[TBL] [Abstract][Full Text] [Related]
13. Cell-targeted, dual reduction- and pH-responsive saccharide/lipoic acid-modified poly(L-lysine) and poly(acrylic acid) polyionic complex nanogels for drug delivery.
How SC; Chen YF; Hsieh PL; Wang SS; Jan JS
Colloids Surf B Biointerfaces; 2017 May; 153():244-252. PubMed ID: 28267669
[TBL] [Abstract][Full Text] [Related]
14. Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant.
Nam HJ; Song MY; Choi DH; Yang SH; Jin HT; Sung YC
Eur J Immunol; 2010 Feb; 40(2):351-8. PubMed ID: 19950168
[TBL] [Abstract][Full Text] [Related]
15. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
[TBL] [Abstract][Full Text] [Related]
16. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T cells engineered with TCR signaling-responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter.
Eskandari SK; Sulkaj I; Melo MB; Li N; Allos H; Alhaddad JB; Kollar B; Borges TJ; Eskandari AS; Zinter MA; Cai S; Assaker JP; Choi JY; Al Dulaijan BS; Mansouri A; Haik Y; Tannous BA; van Son WJ; Leuvenink HGD; Pomahac B; Riella LV; Tang L; Seelen MAJ; Irvine DJ; Azzi JR
Sci Transl Med; 2020 Nov; 12(569):. PubMed ID: 33177180
[TBL] [Abstract][Full Text] [Related]
18. The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.
Wang A; Chandran S; Shah SA; Chiu Y; Paria BC; Aghamolla T; Alvarez-Downing MM; Lee CC; Singh S; Li T; Dudley ME; Restifo NP; Rosenberg SA; Kammula US
Sci Transl Med; 2012 Aug; 4(149):149ra120. PubMed ID: 22932225
[TBL] [Abstract][Full Text] [Related]
19. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
20. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
